We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen’s Xgeva Gains Approval to Prevent Bone Disease From Tumors
Amgen’s Xgeva Gains Approval to Prevent Bone Disease From Tumors
November 24, 2010
The FDA has approved Amgen’s Xgeva to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors, giving the drug a broader than expected label, analysts say.